IL1B and Parkinson disease: HF rTMS administered over 4 w inhibited astrocyte activation and downregulated proinflammatory factors, including tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and IL-6 in 6-OHDA rat PD model and C6 astroglial cells (Kang et al., 2022).